Our results demonstrate that, when compared to healthy controls, Th1 cells from RA patients displayed significantly lower levels of TNFR1, either before or after treatment with adalimumab, while the levels of this receptor on Th17 cells were similar between controls and patients with or without the biologic therapy (Figure 7A). The gene discussed is TNFRSF1A; the disease is rheumatoid arthritis.